Helix BioPharma Corp. (TSX:HBP) said it has appointed Dr. Frank Gary Renshaw as its Chief Medical Officer.
The company said Dr. Renshaw has been with Helix since December 2019 as a consultant and member of the Scientific and Strategic Advisory Board and brings over 20 years of experience as a drug developer within the health care industry.
"Dr. Renshaw will bring to Helix BioPharma his several decades of development experience in oncology-hematology, Molecular/Immuno-Oncology drug research," said Helix CEO Artur Gabor.
READ: Helix BioPharma announces scientific collaboration with University Hospital Tuebingen in Germany
"We look forward to his leadership in helping shape the future of our work at Helix," he added.
Helix is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer, based on the proprietary technology platform DOS47.
Contact the author at jon.hopkins@proactiveinvestors.com